Description: Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.
Home Page: www.vandapharma.com
VNDA Technical Analysis
2200 Pennsylvania Avenue NW
Washington,
DC
20037
United States
Phone:
202 734 3400
Officers
| Name | Title |
|---|---|
| Dr. Mihael H. Polymeropoulos M.D. | Founder, Pres, CEO & Chairman of The Board |
| Mr. Kevin Patrick Moran | Sr. VP, CFO & Treasurer |
| Mr. Timothy Williams | Sr. VP, Gen. Counsel & Sec. |
| Mr. Joakim Wijkstrom | Sr. VP & Chief Marketing Officer |
| Mr. Gunther Birznieks | Sr. VP of Bus. Devel. |
| Mr. Scott L. Howell | Chief People Officer |
| Ms. Elizabeth Van Every | Head of Corp. Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 30.303 |
|---|---|
| Trailing PE: | 68.9091 |
| Price-to-Book MRQ: | 1.1534 |
| Price-to-Sales TTM: | 1.5315 |
| IPO Date: | 2006-04-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 278 |